BN Business News
Añadir empresa →
Esta traducción se está preparando. Mientras tanto, mostramos temporalmente la versión original en inglés.

Negocios · 22/6/20011 min de lectura

Serono, Inc.; Withdrawal of Approval of a New Drug Application; Breokinase®

Traducción automática local · Idioma original de la fuente

Resumen

The Food and Drug Administration (FDA) is withdrawing, without prejudice, approval of a new drug application (NDA) for Breokinase (Urokinase for Injection) held by Serono, Inc., 100 Longwater Circle, Norwell, MA 02061. Serono, Inc., notified the agency in writing that it does not intend to introduce Breokinase into the U.S. market or export Breokinase from the United States, and voluntarily requested that the approval of the application be withdrawn and thereby waived its opportunity for a hearing.

Idioma original de la fuente: Federal Register — Food and Drug AdministrationAbrir el comunicado original →